Merck Raises the Ceiling on Its $70 Billion Dream — and Prices In a 2027 Investment Year

Merck Raises the Ceiling on Its $70 Billion Dream — and Prices In a 2027 Investment Year

Merck's third quarter was solid in the way a large-cap pharma quarter is supposed to be: revenue of $18.1 billion, up 5% (4% ex-FX), and the midpoint of both full-year revenue and EPS guidance nudged higher. The interesting part, as is so often the case with this company, was not the quarter but the arithmetic of the year after it. CFO Caroline Litchfield put a number on the transition: moderate top-line growth in 2027, offset by more than $2 billion of generic and loss-of-exclusivity headwinds across BRIDION, the Januvia family and Adempas, plus operating expenses rising at a mid-to-high single-digit rate.

For 2027, we see it as another year of investment as we invest behind our expansive pipeline and our new product launches to drive long term growth. Specifically, in 2027, we expect moderate top line growth, and that is as a result of the strong contributions we expect from our new product launches, as well as animal health, that will be partially offset by more than $2 billion of headwinds as a result of generic competition and LOE impacting BRIDION, Januvia family of products as well as Adempas.

That is the trade in one breath: give up near-term earnings to buy long-term revenue. And the quarter itself was flattered by timing. Litchfield was unusually explicit about the $550 million purchase-timing benefit — $200 million from KEYTRUDA, $50 million from WINREVAIR, $300 million from vaccines, of which $250 million rolls into 2027 rather than unwinding in the fourth quarter. “A further $300 million relates to our vaccines business, which is predominantly Gardasil. We expect $50 million to unwind in the fourth quarter and the remaining $250 million to unwind in 2027.” — Caroline Litchfield, Chief Financial Officer · 2026-10-29 So the beat is real, the raise is real, and the forward comparison just got harder.

The pipeline is derisking — and management is marking its own paper up

The offset is science, and this quarter it arrived in unusual density. At ESMO, Merck showed the first positive Phase 3 results from its GloboTROfuse O5 study for sac-TMT in recurrent endometrial cancer, with a near seven-month improvement in median overall survival versus chemotherapy. More consequential for the long-term story was entismodigene, the individualized neoantigen cancer vaccine partnered with Moderna, which produced clinically meaningful improvements in recurrence-free and distant-metastasis-free survival in resected stage IIb-IV melanoma. CEO Rob Davis did not hedge: “the landmark validation of a therapeutic cancer vaccine with positive phase 3 data presented for entismodigene as an adjuvant treatment for certain patients with melanoma.” — Robert Davis, Chairman and Chief Executive Officer · 2026-10-29

That is a genuinely new modality rather than a lifecycle extension, and Davis used it — alongside Prometheus, the PD-1/VEGF bispecific and broader sac-TMT indications — to tell investors the mid-2030s target is going up: “we expect now to be raising that number” — Robert Davis, Chairman and Chief Executive Officer · 2026-10-29. Note the specificity of what was excluded from the original $70 billion: no Prometheus, essentially nothing for the PD-1/VEGF asset, and an entismodigene product profile management now says is better than the one it underwrote.

The market has already voted. MRK is up 21% over the last 90 days, sitting roughly 6.5% below its August high, and the multiple has re-rated hard: price to revenue of 4.8x, up 53% year over year. That is a lot of credit extended to assets whose readouts are still ahead of them.

The keyword rotation: from cholesterol to the cancer cliff

The company's own keyword trajectory tells the rotation cleanly. Last quarter LIPFENDRA was the single biggest gainer in Merck's vocabulary — the oral PCSK9 launch dominated the conversation, along with LDL cholesterol as a theme. This quarter LIPFENDRA has fallen out of the top ranks entirely and appears mainly as a Q&A afterthought, with management emphasizing script counts, couponing and a slow build to commercial access in 2027 and Medicare in 2028. The enthusiasm has migrated to oncology.

What sits at the top now is lung cancer and KEYTRUDA LOE — the franchise question and the cliff question, fused. KRAS G12C entered the top five, and Dean Li spent real airtime on the first-line design philosophy of krasirag plus subcutaneous KEYTRUDA as a chemo-free regimen. Meanwhile PD 1 VEGF, a top-six theme two quarters ago, has slipped down the list even as Davis cited it as one of the reasons the $70 billion number rises. That is a divergence worth flagging: the asset management talks about most confidently is the one the NLP ranking says has cooled.

One theme that has quietly inverted is geography. high adoption markets appeared this quarter not as a growth boast but as a litigation map — the Dutch injunction means no subcutaneous supply in Italy, Denmark, the Netherlands, France, Belgium and Ireland. “we will not supply in Italy, Denmark, The Netherlands, France, Belgium, and Ireland. These in general are smaller volume markets” — Johannes J. Oosthuizen, President, Oncology Business Unit and MSD International · 2026-10-29. The US is on track: $830 million of QLEX in the quarter, mostly domestic, with a 30%-40% conversion ambition by end-2027.

What the financials say about the hill

The shape of the numbers explains why management keeps reaching for the word "investment." The latest reported quarter shows operating income of -$683 million, with R&D at $9.7 billion in the quarter. Gross margin slipped to 73.5%, down 4 points year over year. Balance sheet leverage has moved the other way too: effective net cash of -$46.4 billion.

Against that, cash generation remains the ballast. Free cash flow of $4.2 billion in the quarter, up 81% year over year funds the dividend, roughly $3 billion of buybacks this year, and the mid-single-digit expense growth management has promised. The tension is that the market is being asked to underwrite a rising expense line and a shrinking near-term earnings base in exchange for revenue that does not arrive in force until the 2030s.

On the prior call, Davis described the transition as “more of a hill than a cliff” — Robert Davis, Chairman and Chief Executive Officer · 2026-08-04 and predicted “a shallow dip with a fast return back to growth” — Robert Davis, Chairman and Chief Executive Officer · 2026-08-04. He also promised that “of the $70 billion, we are going to derisk substantially all of that by the time we get to 2027” — Robert M. Davis, Chairman and Chief Executive Officer · 2026-02-03. The 2027 guidance is the first quantification of the dip — and it lands with consensus estimates still scattered, which Litchfield acknowledged directly.

What to watch

The near-term catalyst list is dense: the ATLAS UC readout for tultokibart, the Brunello study's companion Barolo trial for remygrimeg, the phase 3 CORAAL study in group 2 pulmonary hypertension, regulatory filings for entismodigene, and a sac-TMT approval decision in endometrial cancer. But the debate that will set the stock is narrower: whether 2027 is the trough investment year or a new baseline. Li's caution on reading the melanoma vaccine data across tumor types — he explicitly warned against over-interpreting low-TMB melanoma signals as a read-through to renal cell carcinoma — is a useful reminder that this pipeline is derisking, not derisked. Davis has convinced the market the science is real. The next twelve months have to prove the earnings math is too.